Serum calprotectin (S100A8/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphoma

ŞUMNU Ş., MEHTAP Ö., MERSİN S., TOPTAŞ T., DAĞLIÖZ GÖRÜR G., GEDÜK A., ...Daha Fazla

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, cilt.43, ss.638-644, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 43
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1111/ijlh.13559
  • Dergi Adı: INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.638-644
  • Anahtar Kelimeler: biomarker, calprotectin, Hodgkin lymphoma, A9, SUPPRESSOR-CELLS, EXPRESSION, DIFFERENTIATION, CARCINOMA, GROWTH, TARC
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Introduction Hodgkin lymphoma (HL) is unusual among malignancies, with inflammation playing such a prominent role in its pathogenesis. S100A8/A9 (calprotectin) is a heterodimeric protein, which has a role in the inflammatory response and oncogenesis. In this study in HL patients, the correlation between serum S100A8/A9 levels and treatment responses was investigated along with whether this marker is correlated with other inflammatory markers.